From the Research
Dosing of Octreotide for Arteriovenous Malformation (AVM)
There is no direct evidence in the provided studies regarding the appropriate dosing of Octreotide (Sandostatin) for Arteriovenous Malformation (AVM).
Treatment Options for AVM
- The treatment of AVMs typically involves a multidisciplinary approach, including conservative measures, transcatheter or percutaneous embolization, and surgical resection 1, 2.
- Embolization is currently the first line of treatment for symptomatic or evolutive AVMs, using agents such as ethanol, glue, or Onyx 2.
- Surgery can be indicated to resect residual AVM following embolization if residual symptoms are present and the planned surgery is feasible, with relative safety 2.
- Medical adjuvants, such as rapamycin, may be considered in the management of surgically refractory AVMs, with some studies showing promising results 3.
Management of AVMs
- The management of AVMs should be done in an interdisciplinary center for vascular malformations, with extensive knowledge of the various therapies, including those from different specialties 1.
- A clinical classification, such as the Schobinger classification, can help determine the appropriate time to start or pursue therapy 2, 4.
- Diagnostic tools, such as color-coded duplex sonography, MRI, and CT imaging, as well as digital subtraction angiography, are essential for the diagnosis and treatment of AVMs 1, 2.